EC adopts Code of Conduct for nanoscience and nanotech research

18 February 2008

*p Europe is in the vanguard of the emerging field of nanosciences and nanotechnologies (N&N), a developing field of science with the potential for major positive impact economically, socially and environmentally, notes the European Commission. Nevertheless, knowledge gaps remain about the impact of these technologies on human health and the environment, as well as issues relating to ethics and the respect of fundamental rights. This is why, the Commission says, it is recommending that European Union member states adopt a Code of Conduct to govern research in this field. Based around seven general principles, the Code of Conduct invites member states to take concrete action, involving universities, research institutes and companies, for the safe development and use of nanotechnologies.

"Nanotechnologies and nanosciences could very well be the next revolution in enabling technologies, and Europe has a good track record in their development," stated European Science and Research Commissioner Janez Potocnik. The seven principles are:

- Meaning: N&N research activities should be comprehensible to the public. They should respect fundamental rights and be conducted in the interest of the well-being of individuals and society in their design, implementation, dissemination and use;

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Company Spotlight